Albertsen P, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565-573.
CASODEX® (bicalutamide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; Approved 1995. Revised October 2017.
Champ CE, Francis L, Klement RJ, et al. Fortifying the treatment of prostate cancer with physical activity. Prostate Cancer. 2016;2016:9462975.
de Wit R, de Bono J., Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506-2518.
Degarelix (prescribing information). Ferring Pharmaceuticals Inc.; Approved 2008. Revised December 2008.
dela Rama F, Pratz C. Navigating treatment of metastatic castration- resistant prostate cancer: nursing perspectives. Clin J Oncol Nurs. 2015;19:723‐732.
Dellis AE, Papatsoris AG. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2019;20:163‐172.
Donovan KA, Gonzalez BD, Nelson AM, et al. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: a controlled comparison. Psychooncology. 2018;27:316‐324.
ELIGARD® (leuprolide acetate) [prescribing information]. Fort Collins, CO: Tolmar Therapeutics, Inc.; Approved 2002. Revised April 2019.
ERLEADA® (apalutamide) [prescribing information]. Horsham, PA: Janssen Products, LP; Approved 2018. Revised September 2019.
Fizazi K, Shore ND, Tammela T, et al. ARAMIS: efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). Presented at: 2019 Genitourinary Cancers Symposium. February 14-16, 2019. San Francisco, CA. Presentation 140.
Flutamide (prescribing information). Chestnut Ridge, NY: Par Pharmaceutical; Approved 1989.
Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465‐2474.
LUPRON DEPOT® (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc.; Approved 1989. Revised March 2019.
Magee D, Singal R. Androgen deprivation therapy: indications, methods of utilization, side effects and their management. Can J Urol. 2020;27(Suppl 1): 11-16.
May MB, Glode AE. Apalutamide: a new agent in the management of prostate cancer. J Oncol Pharm Pract. 2019;25:1968‐1978.
Meani D, Solarić M, Visapää H, et al. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care. Ther Adv Urol. 2017;10:51‐63.
Muehlbauer P, Thorpe A, Davis A, et al. Putting evidence into practice: evidence based interventions to prevent, manage, and treat chemotherapy and radiotherapy induced diarrhea. Clin J Oncol Nurs. 2009;13:336-341.
NCCN Clinical practice guidelines in oncology (NCCN Guidelines®). Prostate Cancer. V1.2020. www.nccn.org. Accessed June 17, 2020.
Nelson CJ, Lee JS, Gamboa MC, et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113:1097‐1106.
Nilutamide (prescribing information). Baudette, MN: ANI Pharmaceuticals, Inc.; Approved 2015. Revised December 2015.
NUBEQA™ (darolutamide) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; Approved 2019. Revised July 2019.
Rodriguez-Vida A, Galazi M, Rudman S, et al. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2015;9:3325‐3339.
Saranyutanon S, Srivastava SK, Pai S, et al. Therapies targeted to androgen receptor signaling axis in prostate cancer: progress, challenges, and hope. Cancers (Basil). 2020;12:51.
Siegel R, Miller K, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408‐1418.
Søgaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3‐29.
Urology Today website. Assessment of Cardiovascular Risk With the Use of Androgen Deprivation Therapy for Prostate Cancer. Updated March 2017. Accessed June 12, 2020. https://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/96381-assessment-of-cardiovascular-risk-with-the-use-of-androgen-deprivation-therapy-for-prostate-cancer-everyday-urology-full-text-article.html
Wadhwa VK, Weston R, Mistry R, et al. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800‐805.
XTANDI® (enzalutamide) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; Approved 2012. Revised December 2019.
YONSA® (abiraterone acetate) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2019.
ZOLADEX® (goserelin acetate) [prescribing information]. Lake Forest, IL: TerSera Therapeutics LLC; Approved 1989. Revised February 2019.
ZYTIGA® (abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; Approved 2011. Revised June 2019.

The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest

Faculty

Victoria Sinibaldi, RN, MS, CS, CANP, CGNP

Adult & Geriatric Nurse Practitioner
Research Associate in Oncology and Urology
Faculty, School of Medicine
Johns Hopkins University
Baltimore, Maryland
Participation by Ms Sinibaldi does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Disclosures

Disclosure: Victoria Sinibaldi, RN, MS, CS, CANP, CGNP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: MCM Education

Emily A. Lemke, DNP, AGPCNP-BC, AOCNP

Nurse Practitioner
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin

Disclosures

Disclosure: Emily A. Lemke, DNP, AGPCNP-BC, AOCNP, has disclosed no relevant financial relationships.

The PIM planners and managers have nothing to disclose.

Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose.

Editors

Davecia Ragoonath-Cameron, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Davecia Ragoonath-Cameron, MS, has disclosed no relevant financial relationships.

Carol Smyth, MB

Director, Content Development, Medscape, LLC

Disclosures

Disclosure: Carol Smyth, MB, has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA

Associate Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CE

The Nursing Intersection: Upregulating Quality of Life During Downregulation of the Androgen Axis

Authors: Victoria Sinibaldi, RN, MS, CS, CANP, CGNP; Emily A. Lemke, DNP, AGPCNP-BC, AOCNP
CE Released: 6/24/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 6/24/2021

Start Activity

Target Audience and Goal Statement

This activity is intended for nurses and nurse practitioners.

The goal of this activity is to educate nursing professionals about current and emerging approaches with oral antiandrogen therapies in the management of locally advanced or metastatic prostate cancer to better recognize and differentiate adverse events (AEs) of therapies that target the androgen axis pathway.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- AEs associated with various therapies aimed at the androgen axis pathway in the management of prostate cancer
- Monitoring of AEs for therapies utilized in androgen axis downregulation in prostate cancer
Have increased confidence regarding
- Counseling points to empower nurses to engage in discussion with patients to optimize adherence and outcomes while on androgen axis deprivation therapies
Have greater competence related to
- Mitigation of androgen axis therapy related AEs

Disclosures

Faculty

Victoria Sinibaldi, RN, MS, CS, CANP, CGNP

Adult & Geriatric Nurse Practitioner
Research Associate in Oncology and Urology
Faculty, School of Medicine
Johns Hopkins University
Baltimore, Maryland
Participation by Ms Sinibaldi does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Disclosures

Disclosure: Victoria Sinibaldi, RN, MS, CS, CANP, CGNP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: MCM Education

Emily A. Lemke, DNP, AGPCNP-BC, AOCNP

Nurse Practitioner
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin

Disclosures

Disclosure: Emily A. Lemke, DNP, AGPCNP-BC, AOCNP, has disclosed no relevant financial relationships.

The PIM planners and managers have nothing to disclose.

Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose.

Editors

Davecia Ragoonath-Cameron, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Davecia Ragoonath-Cameron, MS, has disclosed no relevant financial relationships.

Carol Smyth, MB

Director, Content Development, Medscape, LLC

Disclosures

Disclosure: Carol Smyth, MB, has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA

Associate Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Medscape LLC in collaboration with Postgraduate Institute for Medicine

The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

For Nurses

1.0 contact hours may be earned for successful completion of this activity. Designated for 0.9 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; registered nurses should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive ANCC contact hours, you must receive a minimum score of 66% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

The Nursing Intersection: Upregulating Quality of Life During Downregulation of the Androgen Axis

Authors: Victoria Sinibaldi, RN, MS, CS, CANP, CGNP; Emily A. Lemke, DNP, AGPCNP-BC, AOCNPFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CE Released: 6/24/2020

Valid for credit through: 6/24/2021

processing....

Abbreviations

ACE = angiotensin-converting enzyme
ADT = androgen deprivation therapy
AE = adverse event
AR = androgen receptor
BBB = blood-brain barrier
BMD = bone mineral density
BP = blood pressure
BRAT = bananas, rice, applesauce, toast
CBC = complete blood count
CMP = comprehensive metabolic panel
CNS = central nervous system
CRPC = castration-resistant prostate cancer
CSPC = castration-specific prostate cancer
CVD = cardiovascular disease
DDI = drug-drug interaction
DEXA = dual-energy x-ray absorptiometry
DNA = deoxyribonucleic acid
DOAC = direct oral anticoagulant
DVT = deep vein thrombosis
FSH = follicle stimulating hormone
GnRH = gonadotropin-releasing hormone
IM = intramuscular
IV = intravenous
LFT = liver function test
LH = luteinizing hormone
LHRH = luteinizing hormone-releasing hormone
mCRPC = metastatic castration-resistant prostate cancer
mCSPC = metastatic castration-sensitive prostate cancer
M0 = nonmetastatic
MOA = mechanism of action
nmCRPC = non metastatic castration-resistant prostate cancer
ONS = Oncology Nursing Society
PARP = poly(ADP-ribose) polymerase
PCP = primary care provider
PE = pulmonary embolism
PPI = proton pump inhibitor
PSA = prostate-specific androgen
PSADT = prostate specific antigen doubling time
RCT = randomized controlled trial
trAE = treatment-related adverse event
TSH = thyroid-stimulating hormone

« Return to: The Nursing Intersection: Upregulating Quality of Life During Downregulation of the Androgen Axis

CE Information Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Victoria Sinibaldi, RN, MS, CS, CANP, CGNP

Emily A. Lemke, DNP, AGPCNP-BC, AOCNP

Editors

Davecia Ragoonath-Cameron, MS

Carol Smyth, MB

Yoji Yamaguchi, MA

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CE

The Nursing Intersection: Upregulating Quality of Life During Downregulation of the Androgen Axis

Target Audience and Goal Statement

Disclosures

Faculty

Victoria Sinibaldi, RN, MS, CS, CANP, CGNP

Emily A. Lemke, DNP, AGPCNP-BC, AOCNP

Editors

Davecia Ragoonath-Cameron, MS

Carol Smyth, MB

Yoji Yamaguchi, MA

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Nurses

Instructions for Participation and Credit

The Nursing Intersection: Upregulating Quality of Life During Downregulation of the Androgen Axis

Abbreviations